(Reuters) -British drugmaker GSK on Wednesday bought partner CureVac out of their alliance on influenza and COVID-19 vaccine development, boosting its messenger RNA credentials and extending the ...

GSK plc GSK recently restructured its existing collaboration with Germany-based vaccine maker CureVac N.V. CVAC into a new licensing agreement. Per the latest agreement, GSK will acquire global rights ...

British Pharma giant GSK said on Wednesday it will pay as much as $1.5 billion to take control of several mRNA vaccines from vaccine developer CureVac, sending shares of the struggling German biotech ...

Drugmaker GSK will be paid up to £372m after settling a patent row over Covid vaccines in the US. The London-listed pharmaceuticals giant – previously known as Glaxosmithkline – and German partner ...

Law360 (October 15, 2024, 6:30 PM EDT) -- Moderna's breakthrough COVID-19 vaccine and a related respiratory syncytial virus, or RSV, vaccine were built on mRNA technology discovered by researchers ...

GSK has successfully appealed a ruling by the U.K. marketing watchdog that determined a trio of its COVID-19 vaccine press releases had brought discredit on the pharma industry. The case is the latest ...

Learn about the companies that are manufacturing vaccines and what you should know before investing in vaccine stocks.

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

CureVac (NASDAQ:CVAC) announced on Friday that the company and its partner, GSK (NYSE:GSK), are set to receive $740M and other payments, as Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have agreed to ...

Add Yahoo as a preferred source to see more of our stories on Google. Donald Trump has repeatedly accused Pfizer of helping Joe Biden win the 2020 election - Francis Chung/Politico/Bloomberg Donald ...